Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Aptevo Provides State of the Business Report and 2025 Financial Results
Aptevo to Participate in March 2026 Conferences
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.